Showing 1881-1890 of 2314 results for "".
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- MediPrint Ophthalmics Announces Results from its SIGHT-2 Phase 2b Group 1 Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-results-from-its-sight-2-phase-2b-group-1-clinical-study/2481665/MediPrint Ophthalmics announced it has completed its SIGHT-2 dose-finding phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovati
- Kaustabh Ghosh, PhD, Recognized With Catalyst Award for Innovative AMD Researchhttps://modernod.com/news/dr-kaustabh-ghosh-recognized-with-catalyst-award-for-innovative-amd-research/2481657/Doheny Eye Institute announced that Kaustabh Ghosh, PhD, was recently recognized by non-profits Research to Prevent Blindness (RPD) and the International Retinal Research Foundation (IRRF) with the Catalyst Award for innovative approaches for age-related macular degeneration (AMD). 
- Bausch + Lomb Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United Stateshttps://modernod.com/news/bausch-lomb-launches-biotrue-hydration-boost-contact-lens-rehydrating-drops-in-the-united-states/2481653/Bausch + Lomb announced the US launch of Biotrue Hydration Boost Contact Lens Rehydrating drops, which the company describes as the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior
- Oculis Announces Positive Topline Results from DIAMOND Stage 1 Phase 3 Trial in DME with OCS-01 Eye Dropshttps://modernod.com/news/oculis-announces-positive-topline-results-from-diamond-stage-1-phase-3-trial-in-dme-with-ocs-01-eye-drops/2481628/Oculis announced positive topline results from Stage 1 of its phase 3 DIAMOND trial of OCS-01 eye drops in diabetic macular edema (DME). DIAMOND is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and safety of OCS-01 eye drops in DME